Abstract
DNA molecules containing unmethylated CpG-dinucleotides in particular base contexts (“CpG motifs”) are excellent adjuvants in rodents, but their effects on human cells have been less clear. Dendritic cells (DCs) form the link between the innate and the acquired immune system and may influence the balance between T helper 1 (Th1) and Th2 immune responses. We evaluated the effects of CpG oligodeoxynucleotides alone or in combination with granulocyte–macrophage colony-stimulating factor (GMCSF) on different classes of purified human DCs. For primary dendritic precursor cells isolated from human blood, CpG oligonucleotides alone were superior to GMCSF in promoting survival and maturation (CD83 expression) as well as expression of class II MHC and the costimulatory molecules CD40, CD54, and CD86 of DCs. Both CD4-positive and CD4-negative peripheral blood dendritic precursor cells responded to CpG DNA which synergized with GMCSF but these DCs showed little response to lipopolysaccharide (LPS). In contrast, monocyte-derived DCs did not respond to CpG, but they were highly sensitive to LPS, suggesting an inverse correlation between CpG and LPS sensitivity in different subsets of DCs. Compared with GMCSF, CpG-treated peripheral blood DCs showed enhanced functional activity in the mixed lymphocyte reaction and induced T cells to secrete increased levels of Th1 cytokines. These findings demonstrate the ability of specific CpG motifs to strongly activate certain subsets of human DCs to promote Th1-like immune responses, and support the use of CpG DNA-based trials for immunotherapy against cancer, allergy, and infectious diseases.
References
48
Referenced
473
10.1038/374546a0
10.1073/pnas.94.20.10833
10.1084/jem.186.10.1623
10.1073/pnas.95.26.15553
-
H L Davis, R Weeranta, T J Waldschmidt, L Tygrett, J Schorr, A M Krieg J Immunol 160, 870–876 (1998).
(
10.4049/jimmunol.160.2.870
) / J Immunol by Davis H L (1998) 10.1002/eji.1830270931
10.1182/blood.V89.8.2994
-
S Zimmermann, O Egeter, S Hausmann, G B Lipford, M Rocken, H Wagner, K Heeg J Immunol 160, 3627–3630 (1998).
(
10.4049/jimmunol.160.8.3627
) / J Immunol by Zimmermann S (1998) -
J N Kline, T J Waldschmidt, T R Businga, J E Lemish, J V Weinstock, P S Thorne, A M Krieg J Immunol 160, 2555–2559 (1998).
(
10.4049/jimmunol.160.6.2555
) / J Immunol by Kline J N (1998) 10.1126/science.273.5273.352
10.1073/pnas.95.16.9482
10.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9
10.1084/jem.188.5.809
10.1002/(SICI)1096-9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H
10.1006/cimm.1997.1151
10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7
10.1038/nm0398-328
10.1038/nm0398-321
10.1038/nm0196-52
10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6
10.1016/0022-1759(96)00078-6
- R Mortarini, A Anichini, M Di Nicola, S Siena, M Bregni, F Belli, A Molla, A M Gianni, G Parmiani Cancer Res 57, 5534–5541 (1997). / Cancer Res by Mortarini R (1997)
10.1084/jem.178.3.1067
10.1016/S0171-2985(97)80085-X
10.1089/oli.1.1996.6.291
- G Hartmann, A Krug, M Bidlingmaier, U Hacker, A Eigler, R Albrecht, C J Strasburger, S Endres J Pharmacol Exp Ther 285, 920–928 (1998). / J Pharmacol Exp Ther by Hartmann G (1998)
10.1016/0022-1759(94)90236-4
10.1038/sj.gt.3300880
10.1016/S0264-410X(98)80122-9
10.1084/jem.188.12.2335
-
A M Krieg, H L Love, A K Yi, J T Harty J Immunol 161, 2428–2434 (1998).
(
10.4049/jimmunol.161.5.2428
) / J Immunol by Krieg A M (1998) 10.1089/jir.1997.17.781
10.1046/j.1365-2567.1997.00301.x
-
L J Zhou, T F Tedder J Immunol 154, 3821–3835 (1995).
(
10.4049/jimmunol.154.8.3821
) / J Immunol by Zhou L J (1995) -
D Broide, J Schwarze, H Tighe, T Gifford, M D Nguyen, S Malek, U J Van, O E Martin, E W Gelfand, E Raz J Immunol 161, 7054–7062 (1998).
(
10.4049/jimmunol.161.12.7054
) / J Immunol by Broide D (1998) 10.1007/BF03401902
10.1046/j.1365-2141.1997.4283238.x
-
T Jakob, P S Walker, A M Krieg, M C Udey, J C Vogel J Immunol 161, 3042–3049 (1998).
(
10.4049/jimmunol.161.6.3042
) / J Immunol by Jakob T (1998) 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8
10.1038/30845
10.1038/31002
10.1038/30989
10.1038/30996
-
A K Yi, A M Krieg J Immunol 161, 4493–4497 (1998).
(
10.4049/jimmunol.161.9.4493
) / J Immunol by Yi A K (1998) 10.1074/jbc.270.51.30823
-
A Craxton, G Shu, J D Graves, J Saklatvala, E G Krebs, E A Clark J Immunol 161, 3225–3236 (1998).
(
10.4049/jimmunol.161.7.3225
) / J Immunol by Craxton A (1998) 10.1182/blood.V92.10.3730
10.1007/s002620050507
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 10:38 a.m.) |
Deposited | 2 years, 4 months ago (April 22, 2023, 8:21 a.m.) |
Indexed | 3 weeks, 4 days ago (Aug. 2, 2025, 12:39 a.m.) |
Issued | 26 years ago (Aug. 3, 1999) |
Published | 26 years ago (Aug. 3, 1999) |
Published Online | 26 years ago (Aug. 3, 1999) |
Published Print | 26 years ago (Aug. 3, 1999) |
@article{Hartmann_1999, title={CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells}, volume={96}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.96.16.9305}, DOI={10.1073/pnas.96.16.9305}, number={16}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Hartmann, G. and Weiner, G. J. and Krieg, A. M.}, year={1999}, month=aug, pages={9305–9310} }